Business Description
CSPC Pharmaceutical Group Ltd
SIC : 2834
ISIN : HK1093012172
Total Employee Number:
19,700Description
CSPC Pharmaceutical Group Ltd is a China-based pharmaceutical company engaged in the research, development, manufacture, and sale of pharmaceutical products. Its operations are organized into finished drugs, bulk products, and functional food and other segments. The finished drugs segment is the largest contributor and includes branded medicines in therapeutic areas such as nervous system, oncology, anti-infectives, cardiovascular, and metabolic diseases, along with licensing income. The bulk products segment produces vitamin C and antibiotic products in powder form, serving both domestic and international customers. The functional food segment offers products such as caffeine food additives, anhydrous glucose, and vitamin C supplements, and also provides healthcare services. The company generates most of its revenue from the Chinese mainland, with additional sales in other Asian regions, Europe, North America, and elsewhere. Revenue comes primarily from pharmaceutical sales, supplemented by bulk exports and licensing fees.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 28.42 | |||||
Equity-to-Asset | 0.67 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | 0.06 | |||||
Interest Coverage | 304.37 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 6.33 | |||||
Beneish M-Score | -2.63 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -4.6 | |||||
3-Year EBITDA Growth Rate | -9.3 | |||||
3-Year EPS without NRI Growth Rate | -14.8 | |||||
3-Year FCF Growth Rate | -9.3 | |||||
3-Year Book Growth Rate | 4.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.3 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.35 | |||||
9-Day RSI | 64.38 | |||||
14-Day RSI | 59.93 | |||||
3-1 Month Momentum % | 26.66 | |||||
6-1 Month Momentum % | -3.41 | |||||
12-1 Month Momentum % | -12.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.14 | |||||
Quick Ratio | 1.93 | |||||
Cash Ratio | 1.29 | |||||
Days Inventory | 122.65 | |||||
Days Sales Outstanding | 61.59 | |||||
Days Payable | 109.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 3.33 | |||||
Dividend Payout Ratio | 0.42 | |||||
3-Year Dividend Growth Rate | 7.4 | |||||
Forward Dividend Yield % | 4.08 | |||||
5-Year Yield-on-Cost % | 5.46 | |||||
3-Year Average Share Buyback Ratio | 1.5 | |||||
Shareholder Yield % | 3.18 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 72.01 | |||||
Operating Margin % | 29.07 | |||||
Net Margin % | 24.02 | |||||
EBITDA Margin % | 34.31 | |||||
FCF Margin % | 38.96 | |||||
OCF Margin % | 43.75 | |||||
ROE % | 21.87 | |||||
ROA % | 15.29 | |||||
ROIC % | 28.03 | |||||
3-Year ROIIC % | -26.05 | |||||
ROC (Joel Greenblatt) % | 67.7 | |||||
ROCE % | 24.84 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.95 | |||||
Forward PE Ratio | 14.94 | |||||
PE Ratio without NRI | 12.35 | |||||
Shiller PE Ratio | 21.24 | |||||
Price-to-Owner-Earnings | 19.36 | |||||
PS Ratio | 2.87 | |||||
PB Ratio | 2.33 | |||||
Price-to-Tangible-Book | 2.76 | |||||
Price-to-Free-Cash-Flow | 25.91 | |||||
Price-to-Operating-Cash-Flow | 15.75 | |||||
EV-to-EBIT | 7.94 | |||||
EV-to-Forward-EBIT | 11.83 | |||||
EV-to-EBITDA | 6.91 | |||||
EV-to-Forward-EBITDA | 8.84 | |||||
EV-to-Revenue | 2.38 | |||||
EV-to-Forward-Revenue | 2.35 | |||||
EV-to-FCF | 20.52 | |||||
Price-to-GF-Value | 1.38 | |||||
Price-to-Projected-FCF | 1.72 | |||||
Price-to-Median-PS-Value | 1.01 | |||||
Price-to-Graham-Number | 1.28 | |||||
| Price-to-Net-Current-Asset-Value | 7.5 | |||||
Earnings Yield (Greenblatt) % | 12.59 | |||||
FCF Yield % | 3.82 | |||||
Forward Rate of Return (Yacktman) % | -0.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CSPC Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,854.94 | ||
| EPS (TTM) (€) | 0.081 | ||
| Beta | 0.291 | ||
| 3-Year Sharpe Ratio | 0.45 | ||
| 3-Year Sortino Ratio | 0.9 | ||
| Volatility % | 37.5 | ||
| 14-Day RSI | 59.93 | ||
| 14-Day ATR (€) | 0.03727 | ||
| 20-Day SMA (€) | 1.00598 | ||
| 12-1 Month Momentum % | -12.24 | ||
| 52-Week Range (€) | 0.7331 - 1.171 | ||
| Shares Outstanding (Mil) | 11,405.45 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CSPC Pharmaceutical Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CSPC Pharmaceutical Group Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| HKD 0.180000 Cash Dividend | 2026-10-20 | In 28 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | 0.93 (-2.64%) | ||
| HKD 0.150000 Cash Dividend | 2026-06-24 | 0.76 (+0.45%) | ||
| General meeting for 2025 | 2026-05-28 10:00 | 0.77 (+1.48%) | ||
| First quarter earnings results for 2026 | 2026-05-27 | 0.80 (-1.05%) | ||
| Annual report for 2025 | 2026-04-28 | 0.95 (-0.39%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-25 | 0.91 (+0.71%) | ||
| HKD 0.140000 Cash Dividend | 2025-10-17 | 1.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-22 | 1.14 (+0.00%) | ||
| HKD 0.100000 Cash Dividend | 2025-06-04 | 0.85 (+0.00%) |
Show
Entries
CSPC Pharmaceutical Group Ltd Frequently Asked Questions
What is CSPC Pharmaceutical Group Ltd(STU:CVG)'s stock price today?
The current price of STU:CVG is €1.05. The 52 week high of STU:CVG is €1.17 and 52 week low is €0.73.
When is next earnings date of CSPC Pharmaceutical Group Ltd(STU:CVG)?
The next earnings date of CSPC Pharmaceutical Group Ltd(STU:CVG) is 2027-03-25 Est..
Does CSPC Pharmaceutical Group Ltd(STU:CVG) pay dividends? If so, how much?
The Dividend Yield %  of CSPC Pharmaceutical Group Ltd(STU:CVG) is 3.33% (As of Today), Highest Dividend Payout Ratio of CSPC Pharmaceutical Group Ltd(STU:CVG) was 0.69. The lowest was 0. And the median was 0.29. The  Forward Dividend Yield % of CSPC Pharmaceutical Group Ltd(STU:CVG) is 4.08%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers